The success of the first to the third generation of EGFR inhibitors such as gefitinib, afatinib, and osimertinib in non-small cell lung cancer proved that targeting EGFR pathway in cancer cells is an effective method [31–33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.